The Effect of 14-Day Consumption of Hydrogen-Rich Water Alleviates Fatigue but Does Not Ameliorate Dyspnea in Long-COVID Patients: A Pilot, Single-Blind, and Randomized, Controlled Trial.
Yineng Tan, Yixun Xie, Gengxin Dong, Mingyue Yin, Zhangyuting Shang, Kaixiang Zhou, Dapeng Bao, Junhong Zhou · Nutrients · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
Similarly, no significant differences in the percent changes for these outcomes ( p = 0.441~0.657) from baseline to post-intervention were observed between the HRW and PW groups.
What the Researchers Studied
The study used a randomized, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 1600 ppb H₂ (≈1.6 mg/L); Source-reported hydrogen exposure: 500 mL hydrogen-rich water per serving, 2 servings/day; approximately 0.80 mg H₂ per reported serving; H2HUBB calculated daily H₂ dose: approximately 1.6 mg H₂/day, calculated from the source-reported dissolved H₂ concentration and total hydrogen-water volume consumed per day. Similarly, no significant differences in the percent changes for these outcomes ( p = 0.441~0.657) from baseline to post-intervention were observed between the HRW and PW groups. The authors concluded that this study demonstrates that HRW might be an effective strategy for alleviating fatigue and improving cardiorespiratory endurance, musculoskeletal function, and sleep quality. Hydrogen (H₂) may be a potential therapeutic agent for managing Long COVID symptoms due to its antioxidant and anti-inflammatory properties.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The reported sample size was 55. The study used a randomized, placebo-controlled human clinical trial. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen concentration was 1600 ppb H₂ (≈1.6 mg/L). The source-reported hydrogen exposure was 500 mL hydrogen-rich water per serving, 2 servings/day; approximately 0.80 mg H₂ per reported serving. H2HUBB calculated daily H₂ dose: approximately 1.6 mg H₂/day, calculated from the source-reported dissolved H₂ concentration and total hydrogen-water volume consumed per day. This is a deterministic dose translation, not a separately measured value.
Limitations and Safety
Reported limitations: On the other hand, the researchers did not observe significant improvements in mood induced by HRW compared to those provoked by PW among those with depression and/or anxiety, which may be due to the relatively small sample size of the subgroup with mood symptoms and many confounders (e.g., economic stress, family isolation, and various social contact restrictions) that may interfere with the effects of H₂ [ 43, 44 ].
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.